GE Medical Holding AB has exercised all 26,973,169 warrants it holds in EXACT Therapeutics, resulting in gross proceeds of NOK 33 million for the clinical-stage precision medicine company. The warrant exercise follows a positive safety read-out from EXACT Therapeutics’ phase 2 ENACT trial in locally advanced pancreatic cancer, announced on 27 January 2026. Other warrant holders have until 26 February 2026 to exercise their rights.
EXACT Therapeutics develops ultrasound-activated drug therapies, including PS101, aimed at enhancing cancer treatment. The recent trial data showed encouraging tumor shrinkage and a significant decrease in the tumor biomarker CA 19-9. GE Medical Holding AB is a subsidiary of GE HealthCare Technologies Inc. and expressed support for advancing EXACT’s therapy development.
**Why this matters**
The warrant exercise provides EXACT Therapeutics with additional funding to continue its clinical development, particularly the ENACT phase 2 trial. Positive trial results and financial backing from a major healthcare company like GE HealthCare may enhance the company’s prospects in developing new treatments for pancreatic cancer, a disease with limited effective options.
Source: NewsData